Skip to content

Evaluation of tumor hypoxia for stereotactic radiotherapy using F-18 fluoromisonidazole

Evaluation of tumor hypoxia for stereotactic radiotherapy using F-18 fluoromisonidazole - Evaluation of tumor hypoxia for stereotactic radiotherapy using F-18 fluoromisonidazole

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000028332
Enrollment
18
Registered
2017-07-24
Start date
2017-03-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

To perform F-MISO PET/CT before and 1 day after treatment To perform F-MISO PET/CT before and 2 day after treatment To perform F-MISO PET/CT before and 3 day after treatment

Sponsors

Kindai University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Adaptable of stereotactic radiotherapy for primary or metastatic lung malignant tumor less of equal 5cm. Fulfilling both of the following conditions and clinically diagnosed as NSCLC. a) increase in tumor size of 1 mm or more, or consolidation/tumor ratio turning >50% from <=50% on CT scans performed 28 days or more apart. b) positive accumulation on FDG-PET. 2)Performance status (ECOG): 0-2 3)Enable for performing PET/CT 4)Aged 20 to 84 5)signed informed consent

Exclusion criteria

Exclusion criteria: 1)During the pregnancy or a pregnant female patient we are possible or are nursing. 2)The patient whom we merge psychosis or neurological manifestation, and it is judged to have difficulty with participation to an examination. 3)Severe complications whom enable to perform PET/CT 4)Other reasons with inadequate to enroll this trial

Design outcomes

Primary

MeasureTime frame
Change of 18F-MISO uptake between before and after treatment

Countries

Japan

Contacts

Public ContactMasahiro Inada

Kindai University Department of Radiation Oncology,

im022012@med.kindai.ac.jp072-366-0221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026